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10-Jahres Epidemiologie der Infektiösen Endokarditis – Vergleich zwischen 
Histopathologie, Mikrobiologie und klinischer Präsentation 
 
Hintergrund: Eine optimale Behandlung der infektiösen Endokarditis setzt einen 
frühen Erregernachweis, ein gründliches Wissen über die klinische Präsentation, das 
lokale Erregerspektrum, und die adäquate antimikrobielle und chirurgische 
Behandlung voraus. 
 
Ziele: I) Erfassen von Epidemiologie und klinischem Auftreten von infektiöser 
Endokarditis (IE) bei Patienten mit Herzklappenoperationen wegen IE am Klinikum 
der Universität Regensburg. Vergleich dieser Daten mit anderen nationalen und 
internationalen Kohortenstudien. II) Vergleich von Nativklappenendokarditis (NVE) 
mit Prothesenklappenendokarditis (PVE) III) Korrelation von Keimart mit 
anatomischer Lage, klinischer Präsentation und histopathologischen 
Schadensmustern von betroffenen Herzklappen. 
 
Methoden: In einer retrospektiven Studie wurden zwischen September 1994 und 
Februar 2005 alle 211 intraoperativ bestätigten Endokarditisepisoden (205 Patienten) 
am Klinikum der Universität Regensburg analysiert.  
 
Ergebnisse: Eine NVE zeigte sich in 84%, eine PVE in 16% der Episoden. Ein 
alleiniger Aortenklappenbefall fand sich in 49%, ein alleiniger Mitralklappenbefall in 
28%, ein kombinierter Aorten- und Mitralklappenbefall in 18%, ein Befall des rechten 
Herzens in 4%, und ein gleichzeitiger Befall des linken und des rechten Herzens in 
1% der IE Episoden. S. aureus wurde in 20% der Fälle nachgewiesen, S. viridans in 
14%, Enterokokken in 9.5%, Streptokokken außer S. virdians (SOTSV) in 8.5%, S. 
epidermidis in 6%, sonstige Keime in 9.5%, und Doppelinfektionen in 4%. 
Kulturnegative Endokarditis (CNE) trat in 32% der Episoden auf. In 38% aller Fälle 
lag begleitend eine Sepsis vor, in 34% traten Embolien auf. Die Letalität betrug 10% 
für die ersten 15 Tage und 14% für die ersten 30 Tage nach Operation. S. aureus 
präsentierte sich von allen Erregern mit dem höchsten Anteil an Sepsis (81%), 
septischen Streuherden (45%), Embolien (64%), cerebralen Embolien (45%) und 
wies unter allen Erregern die höchste Letalität (21%) auf. Enterokokken IE zeigte die 
höchste Abszessrate (60%) und betraf bevorzugt nur die Aortenklappe (70%). S. 
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viridans trat in 97% fast ausschließlich bei Nativklappen auf und hatte die höchste 
Perforationsrate (90%). Histopathologische Ergebnisse zeigten keine signifikante 
Korrelation mit den verursachenden Erregern. 
 
Folgerungen: Mit Ausnahme eines relativ hohen Anteils an CNE zeigte sich die 
Epidemiologie der infektiösen Endokarditis in dieser Studie weitgehend 
übereinstimmend mit Resultaten aus vergleichbaren nationalen und internationalen 
Studien. Die Letalitätsraten in dieser Population lagen im Bereich von vergleichbaren 
Studien. Die Endokarditiden unterschieden sich deutlich in ihrem klinischen 
Erscheinungsbild, je nach verursachendem Erreger. Die Histopathologie der 
entfernten Klappen zeigte jedoch keine Keim-spezifischen Schadensmuster.  
Aufgrund der Beobachtungen in dieser Untersuchung erscheint die 
histopathologische Aufarbeitung von Herzklappen nicht sinnvoll. Stattdessen sollte 
die mikrobiologische Diagnostik nicht nur Blutkulturen, sondern wann immer möglich 
auch Kulturen aus reseziertem Klappengewebe umfassen. Zudem sollten neue 
Techniken wie bakterielle PCR aus entferntem Klappenmaterial etabliert werden, 
was speziell für Endokarditisepisoden mit fehlendem Keimnachweis interessant 
erscheint.   
 
Schlüsselwörter: Infektiöse Endokarditis, Epidemiologie, Erreger, Klappenersatz, 
Nativklappenendokarditis, Prothesenklappenendokarditis 
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10-Year Epidemiology of Infective Endocarditis –  Correlations between 
Histopathology, Microbiology and Clinical Presentation 
 
Background: Optimal management of IE depends on the early detection of IE-
causing pathogens, knowledge of the clinical presentation of the local pathogen 
spectrum and appropriate antimicrobial and surgical therapy.  
 
Objectives: I) To describe the epidemiology and clinical presentation of patients 
receiving heart valve surgery for infective endocarditis (IE), and to compare these 
data with national and international cohort studies. II) To correlate native valve 
endocarditis (NVE) episodes with prosthetic valve endocarditis (PVE) episodes. III) 
To correlate pathogens with anatomic locations, clinical findings and histopathologic 
damage patterns of affected heart valves.  
 
Methods: 211 intraoperatively confirmed endocarditis episodes (in 205 patients) 
between September 1994 and February 2005 were reviewed. Data were extracted 
from surgical records, microbiology results, histopathology reports, in-house charts 
and medical charts of admitting hospitals, whatever appropriate.  
 
Results: NVE was present in 84% and PVE in 16%. The aortic valve was affected in 
49%, the mitral valve in 28%, the aortic and mitral valve in 18%, valves of the right 
heart in 4%, and both valves of the left and the right heart in 1% of all IE episodes. S. 
aureus accounted for 20%, S. viridans for 14%, Enterococci for 9.5%, Streptococci 
other than S. virdians (SOTSV) for 8.5%, S. epidermidis for 6%, miscellaneous 
pathogens for 9.5%, and mixed infections for 4%, respectively. Culture-negative 
endocarditis (CNE) was found in 32%. Sepsis was present in 38% and emboli 
occurred in 34% of all episodes. Mortality was 10% in a 15-day postoperative period 
and 14% in a 30-day period. S. aureus infections had high rates of sepsis (81%), 
septic foci (45%), embolic events (64%), cerebral-embolic events (45%), and a high 
30-day mortality (21%). Infections by Enterococci showed the highest abscess rate 
(60%) and predominately affected the aortic valve (70%). S. viridans infections 
almost exclusively affected native valves (97%) and had the highest perforation rate 
(90%). Histopathological findings did not show any significant correlations with 
pathogens. 
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Conclusions: Results on IE epidemiology confirmed findings of previous studies 
except for a higher CNE infection rate, which differed remarkably from rates found in 
other investigations. Mortality in this cohort was similar to that in previous studies. 
The clinical presentation of IE differed remarkably, depending on the pathogen. In 
contrast, histopathological findings did not reveal pathogen-specific damage patterns 
and added little information overall. According to the results of this study, 
histopathological workup of resected heart valves can be omitted. Instead, in addition 
to blood cultures, microbiological testing should be complemented with cultures of 
resected valve tissue whenever possible. Furthermore, new techniques such as 
bacterial PCR on resected valve tissue should be established as routine diagnostic 
tool and might be especially helpful in culture-negative IE.  
 
Keywords: infective endocarditis, epidemiology, pathogen, valve replacement, 
native valve endocarditis, prosthetic valve endocarditis, valvular damage, damage 
pattern 
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Introduction:  
 
Infective endocarditis (IE) is a bacterial or fungal infection of the inner structures of 
the heart, most often involving heart valves of the left heart, rarely of the right heart or 
both sides. Infection restricted to the endocardium without involvement of heart valve 
structures is uncommon. Damage of the heart valves is a major complication and 
worsens the prognosis of IE. Leaflet perforations, chordae tendineae ruptures and 
annulus dehiscences lead to valve insufficiencies and valve prolapses with 
detrimental effects on the circulation. Vegetations and abscesses bear the risk of 
thrombus generation, which may cause embolic events and metastatic spread of the 
infection. The incidence of IE has considerably decreased in western countries and is 
nowadays estimated to be 20-70 cases per million inhabitants1-3.  
The management of IE requires knowledge and expertise, and it is a challenge to 
decrease mortality below today’s 10-18%1, 4, 5. Multiple reasons are responsible for 
this lack of progress.  
The aging of western societies and medical treatment provides an increasing number 
of multimorbid and immunocompromised patients. Temporal trends show increasing 
intravenous drug abuse, decreasing rheumatic endocarditis, an increase in 
antimicrobial resistance, and an increasing use of invasive diagnostic and therapeutic 
procedures6-9. As a consequence, the spectrum of organisms causing endocarditis 
currently undergoes changes, which has implications on IE treatment.  
Optimal management of IE depends on accurate knowledge of the clinical 
presentation10, the local pathogen spectrum, prompt detection of IE-causing 
pathogens, and adequate antimicrobial and appropriate surgical therapy11.  
This study adds information on the epidemiology and clinical presentation of IE for 
the region of Eastern Bavaria, and the data should be generalizable for other western 
countries5, 11, 12. Data from patients receiving heart valve surgery for IE at the 
Regensburg University Medical Center were collected, analysed and compared to 
published data. The aim of this study was to deliniate damage patterns and 
differences in clinical presentation associated with various pathogens and to evaluate 
the role of pre- and postoperative diagnostic procedures. Therefore, identified 
pathogens were correlated with anatomic locations, clinical findings and 
histopathologic damage patterns of affected heart valves 
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Materials and Methods: 
 
Study Design: 
This retrospective single center study was performed at the Div. of Infectious 
Diseases, Dept. of Internal Medicine I in cooperation with the Dept. of Cardiothoracic 
and Vascular Surgery at Regensburg University Medical Center (tertiary university 
hospital). Data from 205 caucasian patients from the region of Eastern Bavaria, who 
underwent heart surgery for IE were analysed. Patients were diagnosed with IE using 
the modified Duke criteria for the diagnosis of infective endocarditis13, 14. The period 
of investigation comprised more than 10 years (September 1994 to February 2005). 
Data were extracted from the in-house information system of the Department of 
Cardiothoracic and Vascular Surgery. Only patients with intraoperatively confirmed IE 
were included into the study. Data were complemented with microbiological and 
histopathologic reports as well as information from in-house charts and medical 
charts of admitting hospitals, whatever appropriate. Extracted data were thoroughly 
reviewed and analyzed by two independent investigators (F.Z., F.A.) in order to 
prevent systematic and observational errors. Due to incomplete or inconsistent 
documentation, five patients were excluded from the study.  
 
Data Collection:     
Surgical records and medical charts were available for all cases, and provided basic 
information on sex, age, type of endocarditis (NVE vs PVE), location of IE (affected 
valves), type of valve surgery (replacement vs reconstruction), and type of valve 
replacement (biological vs mechanical), if applicable. Details concerning valve 
condition and valvular damage were collected for each patient, such as damage 
on/below/above valve level, bicuspid valve, valve insufficiency, valve stenosis, valve 
prolapse, perforation of valvular cusps, abscesses, vegetations, vegetation thrombi, 
and other types of damage.  
In-house charts and medical charts of admitting hospitals were screened for 
information on presence of diabetes mellitus, sepsis (including sepsis, severe sepsis 
and septic shock episodes), septic metastatic foci, embolic events, relevant 
comorbidities, diagnostic procedures (echocardiography, microbiology, 
histopathology, intraoperative diagnosis), 15-, 30- and 90-day mortality, and 
durations of intensive care unit (ICU) / intermediate care unit (IMC) and hospital stay.  
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Histopathologic examination was available in 89% of all IE episodes (NVE: 95.5%; 
PVE: 56%). Histopathology reports offered exact endocarditis diagnoses and added 
information on valvular damage patterns of the resected tissue: type and location of 
valvular damage, vegetations, bacterial colonization, calcifications, fibrin deposits, 
ulcerations, necrosis, presence of lymphocytes or granulocytes, abscesses, 
vegetation thrombi, perforation of valvular cusps and other types of damages.  
Data on pathogens were extracted from the database of the Institute of Microbiology 
and Hygiene and from reports of admitting hospitals. Type of specimen and isolated 
pathogens were recorded. Blood cultures were done in all episodes. Additionally, in 
5% of the episodes resected tissue, and in 1% thrombotic material or central venous 
catheters were sent for culture. Standard variables were defined for all parameters, 
and combined data were thoroughly reviewed and crosschecked. 
 
Statistical Analysis: 
Data were entered in Microsoft Excel 2000 9.0.2812. (Microsoft Corporation ©1985-
1999), and subsequently transferrred into SPSS 12.0.0. (SPSS Inc. ©1989-2003) for 
statistical calculation. Descriptive data were extracted and variables were compared 
using the Chi-Square Test, Likelihood Ratio and Fisher’s Exact Test, when 
appropriate. For statistical reasons, eight episodes with two detected pathogens 
(mixed infections) were not included in the correlation calculations. A p-value of 0.05 
was considered statistically significant. 
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Results: 
 
Patient characteristics and diagnostic procedures 
205 patients underwent 211 endocarditis episodes in the observation period between 
September 1994 and February 2005. Surgery was performed on 252 heart valves 
(see Table 1). 84% of the IE episodes involved native valves (NVE) and 16% 
prosthetic valves (PVE). Echocardiography was documented in 98% of all cases. In 
detail, transesophageal echocardiography (TEE) was applied in 25%, transthoracal 
echocardiography (TTE) in 1%, and transesophageal and transthoracal 
echocardiography (TEE+TTE) in 25% of all episodes. Echocardiography was 
documented, but not further specified in 47%. In 2% application of echocardiography 
was not documented. In 95% of the IE episodes this diagnostic method allowed to 
make a provisional diagnosis of IE, either by showing valvular perforation, valve 
prolapse, valve insufficiency, dehiscence of the valvular ring, regurgitation, 
vegetations or vegetation thrombi.  
Patient characteristics are summarized in table 1. Median age at the time of surgery 
was 61 years (range 22 to 80, mean: 58). PVE and NVE patients had similar median 
age and sex ratio. Male patients accounted for 75%, female for 25%. 24% of all 
patients had diabetes mellitus as a risk factor. In 38% of all episodes, patients met 
sepsis criteria at the time of surgery with no significant difference between NVE and 
PVE patients (39.5% vs 32%, p>0.4). Septic metastatic foci were present in 23% of 
all cases. Embolic events were documented in 34% of all IE episodes.  
 
Valves affected with IE 
Affected valves were located in the left heart in 95%, in the right heart in 4%, and in 
the left and the right heart in 1%. The distribution of infected valves was as follows: 
aortic valve 49%, mitral valve 28%, aortic and mitral valve 18%, tricuspid valve 3%, 
pulmonary valve 1%, and combined affection of valves in the left and the right heart 
1%. In 81% of all episodes one valve was the only site of IE. Multiple valves were 
significantly more often affected in NVE than in PVE (21.5% vs 6%, p<0.04). 
Endocarditis was present at the aortic valve only at a significantly higher rate in the 
PVE than in the NVE group (70.5% vs 44.5%, p<0.01). 91.5% of all affected valves 
showed insufficiencies. NVE was significantly more often associated with 
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insufficiency than PVE (95% vs 76.5%, p<0.01). Stenosis was present in 13% of all 
episodes. 8.5% of all native aortic valve IE episodes occurred at a bicuspid valve.  
 
Surgical Procedures 
83% of all surgical procedures were primary interventions, 17% reinterventions. 97% 
of the reinterventions were performed in the PVE group. Single valve surgery was 
performed in 90%, and multiple valve surgery in 9% of all episodes, the latter in NVE 
cases only. In PVE episodes mechanical valves were implanted in 59%, biological 
valves in 38%, and valves were reconstructed in 3%. In NVE episodes mechanical 
valves were implanted in 58%, biological valves in 16%, and valve reconstruction 
was done in 15%. In 11% of the NVE episodes multiple surgery was performed. In 
two NVE episodes (1%) the type of valve replacement could not be determined 
retrospectively.  
 
Histopathology 
Surgical and histopathological records documented perforation of valvular cusps in 
71% of all episodes. In 30% of all episodes valve chordae were ruptured, resulting in 
valve prolapses. Valvular damages not further specified occurred in 21% of the 
episodes. Abscesses at the valve ring were present in 31% of all episodes. PVE 
showed significantly more abscesses than NVE (59% vs 26%, p<0.01). Vegetations 
were present in 88%, vegetation thrombi in 55% and calcifications in 84%. Valves 
showed fibrin deposits in 84%, ulcerations in 33% and necrotic areas in 32%. 
Bacterial colonization was present in 25% and lymphocytes in 23%. Granulocytes 
were significantly more often present in the NVE group than in the PVE group (63% 
vs 32%, p<0.01). 
 
Outcome 
Median time of IMC or ICU stay was 4 postoperative days (mean: 7 days), and 
median time of hospital stay 13 days (mean: 15 days).  
Mortality after cardiac surgery was 10% for a 15-day period, 14% for a 30-day period, 
and 17% for a 90-day period, respectively, 30-day mortality decreased from 17% 
between 1994 and 1999 to 12% between 2000 and 2005 (p>0.2). Median time to 
death in the 30-day period was 7 days after surgery (mean: 9 days). 30-day mortality 
of patients younger than 60, between 60 and 70, and older than 70 was 8.5%, 18% 
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and 22% respectively. The difference in mortality between patients younger than 60 
and those older than 70 years was statistically significant (p=0.04). Gender did not 
influence mortality. 15-day mortality of patients with NVE and PVE was 8.5% and 
21% (p=0.052). 30-day and 90-day mortality was significantly higher in PVE than in 
NVE (11% vs 29%, p<0.01,  and 14% vs 32%, p<0.01, respectively). Patients who 
received a single valve replacement with a bioprosthesis had a significantly higher 
30-day mortality compared to patients who received a single valve replacement with 
a mechanical valve (29% vs 14%, p<0.03). Involvement of multiple valves in the IE 
episode, diabetes, sepsis, septic metastatic foci, embolic events or cerebral-embolic 
events were not associated with higher mortality. Furthermore, histopathological 
variables (presence of calcification, fibrin deposit, ulcerations, necrosis, bacterial 
colonization, vegetation, abscesses, valvular perforation, insufficiency or prolapse) 
showed no association with mortality. However, presence of vegetation thrombi on 
the valves was significantly associated with a higher 30-day mortality rate (19% vs 
8%, p<0.03).  
 
Microbiologic results and correlations to other parameters 
Microbiologic identification of causative pathogens was successful in 68% of all IE 
episodes (see Table 2). Blood cultures were drawn in all IE episodes. Resected valve 
tissue was sent for culture in 11 episodes (5%), of which 10 episodes led to the 
identification of the IE-causing pathogen. In two episodes the culturing of thrombotic 
material and a pacer wire led to positve results.  
S. aureus was responsible for 20% of all IE episodes, S. viridans for 14%, 
Enterococci for 9.5%, Streptococci other than S. virdians for 8.5%, S. epidermidis for 
6% and miscellaneous pathogens for 6%. In another 8 episodes (4%) two pathogens 
were isolated. 32% of the episodes were culture negative, two episodes of these 
(1%) were presumably due to rheumatic endocarditis. Viridans streptococci could be 
divided into four groups: unspecified S. viridans spp. (5%), S. mitis (4%), S. sanguis 
(3%) and S. anginosus ( formerly “S. milleri”; 2%). Enterococci were differentiated 
into Enterococcus faecalis (6%), unspecified Enterococcus spp. (2.5%) and 
Enterococcus faecium (1%). Streptococci other than S. viridans (SOTSV) comprised 
S. bovis (4%), S. agalactiae (1%), S. pneumoniae (1%), and several unspecified 
Streptococci: S. haemolyticus (group C, 1%), ß-haemolyzing Streptococcus (0.5%), 
S. equisimilis (0.5%) and S. anhaemolyticus (0.5%).  
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Miscellaneous pathogens represented a heterogenous group of 11 different 
pathogens (see Table 2): Escherichia coli (1%), Aerococcus viridans (0.5%), Candida 
albicans (0.5%), Enterobacter cloacae (0.5%), Gemella morbillorum (0.5%), 
Propionibacterium acne (0.5%), Staphylococcus caprae (0.5%), Staphylococcus 
xylosus (0.5%), Stenotrophomonas maltophilia (0.5%), one unspecified 
Staphylococcus spp. (0.5%) and one unspecified Gram-positive Coccus (0.5%).  
Pathogen spectra differed between NVE and PVE episodes (see Table 1). S. aureus 
was the most prevalent pathogen in the NVE group (21.5%). Among all episodes, S. 
aureus affected the mitral valve at the highest rate (40.5%). There were significant 
lower rates of mitral valve affection by SOTSV (6%; p<0.01), miscellaneous 
pathogens (8%, p<0.03) and Enterococci (10%, p<0.02). Patients with S. aureus IE 
showed a significantly higher perioperative sepsis rate (81%) than patients with IE 
due to other pathogens such as Enterococci (55%, p<0.04), S. epidermidis (46%, 
p<0.02), SOTSV (50%, p<0.02), S. viridans (27%, p<0.01), miscellaneous pathogens 
(17%, p<0.01), and CNE (13%, p<0.01). S. aureus IE showed a significantly higher 
rate of embolic events (64%) than IE episodes by Enterococci (10%, p<0.01), S. 
epidermidis (31%, p<0.04), S. viridans (33%, p=0.01), CNE (19%, p<0.01), or 
miscellaneous pathogens (17%, p<0.01). Only patients with IE due to SOTSV had a 
similar rate of embolic events (67%). IE due to S. aureus also caused a higher rate of 
cerebral-embolic events (45%) than IE due to other pathogens; S. viridans (17%, 
p<0.02), miscellaneous pathogens (8%, p<0.02) and CNE (6%, p<0.01) showed 
significantly less cerebral-embolic events. Septic metastatic foci occurred in 45% of 
the episodes caused by S. aureus, which was of similar magnitude as in episodes 
caused by Enterococci and SOTSV (45% and 39%). IE episodes due to S. viridans 
(20%, p<0.03), miscellaneous pathogens (8%, p<0.02), and CNE (6%, p<0.01) 
showed significantly less septic metastatic foci. These observations are in agreement 
with histopathological results, showing S. aureus IE to have the highest rate of 
vegetation thrombi (74%). In contrast, S. aureus IE showed calcifications in the 
second lowest rate (72%), IE episodes due to S. viridans and CNE had a significantly 
higher calcification rate (93%, p<0.03, and 95%, p<0.01, respectively). SOTSV IE 
episodes had the lowest calcification rate, not significantly different from episodes 
caused by S. aureus. 30-day mortality rate was higher in S. aureus IE episodes 
(21%) than in episodes caused by other pathogens, but the difference did not reach 
statistical significance.  
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S. epidermidis was associated with PVE in 46% of the IE episodes with this 
pathogen, and represented the leading pathogen in the PVE group (17.5%). S. 
epidermidis IE involved most often only a single valve (92%). Valve insufficiency was 
present in 69%, which represented the lowest prevalvence of all pathogens, and was 
significant lower than in IE caused by S. viridans (100%, p=0.001), SOTSV (100%, 
p<0.01), Enterococci (100%, p<0.01), and S. aureus (93%, p<0.04). In no episode 
with this pathogen valvular stenosis was seen.  
S. viridans appeared significantly more often in NVE than in PVE (16% vs 3%, 
p<0.02). S. viridans showed the highest valve perforation rate of all pathogens (90%), 
which was significantly higher than in IE caused by S. epidermidis (54%, p=0.01) or 
CNE (54%, p<0.01). S. viridans IE also showed the highest prolapse rate (47%), 
although this was not significantly different from IE caused by other pathogens.  
Enterococci appeared at similar rates in NVE and PVE (10% and 9%, 
respectively). In 70% of IE episodes by Enterococci, only the aortic valve was 
affected. This was significantly higher than in IE caused by S. aureus (40.5%, 
p<0.01) or S. viridans (37%, p<0.03). Patients with Enterococcal IE showed the 
second highest sepsis rate (55%), significantly higher than in IE caused by S. 
viridans (27%, p<0.05), miscellaneous pathogens (17%, p<0.03) or CNE (13%, 
p<0.01). Enterococci caused the lowest rate of embolic events (10%) or cerebral-
embolic events (0%). Both of these rates were lower than in IE caused by SOTSV 
(67%, p<0.01, and 28%, p<0.01, respectively) or S. aureus (64%, p<0.01, and 45%, 
p<0.01, respectively), even though vegetations at the valves were present in all 
Enterococcal IE cases. Prevalvence of vegetations was not significantly different 
between the different pathogen groups, except for patients with IE caused by CNE; 
those showed significantly less vegetations (71%, p<0.01). Local valve or valvular 
ring abscesses occurred in 60% in Enterococcal IE, which was the highest rate 
compared to IE episodes caused by other pathogens. S. aureus (33%, p<0.05) and 
CNE cases (18%, p<0.01) presented significantly less often with local abscesses.  
SOTSV caused NVE and PVE episodes similarly often, in 8.5% and 9%, 
respectively. In this group the mitral valve was involved in only 6%, a much lower rate 
than seen in IE caused by other pathogens. CNE and S. aureus had significantly 
higher rates of mitral valve involvement (35.5%, p<0.02, and 40.5%, p<0.01, 
respectively). Embolic events happened more often in SOTSV IE (67%) than in all 
other IE episodes. Only S. aureus IE showed an embolic event rate of similar 
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magnitude (64%). IE caused by other pathogens had a significantly lower embolic 
event rate: S. viridans (33%, p<0.03), S. epidermidis (31%, p<0.05), CNE (19%, 
p<0.01), miscellaneous pathogens (17%, p<0.01) and Enterococci (10%, p<0.001). 
SOTSV IE caused the lowest calcification rate (53%) of all groups. Enterococci, S. 
viridans and CNE had significantly more calcifications (85%, p<0.04; and 93%, 
p<0.01; and 95%, p<0.01, respectively). 
Pathogens classified into the heterogeneous group miscellaneous pathogens were 
found in similar freqency in NVE and PVE episodes (5% vs 9%).  More than one 
valve was affected by these pathogens in the highest rate of all pathogen groups 
(58%), significantly higher than in IE episodes by S. aureus (12%, p<0.03), CNE 
(12%, p=0.02) or S. epidermidis (8%, p=0.04). Patients with miscellaneous 
pathogens had low rates of sepsis (17%), septic metastatic foci (8%), embolic events 
(17%) and cerebral-embolic events (8%). Moreover, IE by these pathogens were 
associated with low rates of local abscesses (25%) and valve prolapses (17%), but 
the differences were not significant. 30-day mortality in IE due to miscellaneous 
pathogens was very low (8%), but not significantly different to IE due to other 
pathogens.  
CNE occurred in similar rates in NVE and PVE episodes (32% vs 35%, respectively). 
Patients with CNE met sepsis criteria in only 13% of the cases. This was significantly 
lower than in IE caused by S. epidermidis (46%, p<0.02), SOTSV (50%, p<0.01), 
Enterococci (55%, p<0.01) and S. aureus (81%, p<0.01). CNE showed the lowest 
rate of septic metastatic foci (6%),  significantly less than in IE due to S. viridans 
(20%, p<0.05), SOTSV (39%, p<0.01), Enterococci (45%, p<0.01), and S. aureus 
(45%, p<0.01). In CNE episodes, valvular vegetations were present in a lower rate 
(71%) than in other IE cases. Vegetations were significantly more prevalent in IE due 
to Enterococci (100%, p<0.01), S. aureus (98%, p<0.01), SOTSV (94%, p<0.02), and 
S. viridans (93%, p<0.02). In contrast, CNE presented with the highest rate of 
valvular stenosis (22%).  
According to histopathology results, valve calcifications were present in 95% of the 
CNE episodes, which was the highest rate among all IE. S. aureus IE (72%, p<0.01) 
and SOTSV  IE (53%, p<0.01) had significantly lower calcification rates. Patients with 
CNE showed low rates of fibrin deposit (32%), ulcerations (18%), necrosis (14.5%), 
bacterial colonization (13%) and granulocyte infiltrations (45%). IE episodes caused 
by Enterococci, SOTSV, and miscellaneous pathogens had significantly higher rates 
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of fibrin deposit (61%, p<0.03; and 65%, p<0.02; and 70%, p<0.03) than IE episodes 
due to CNE. Similarly, patients with IE episodes due to S. aureus, Enterococci, and 
SOTSV developed ulcerations at a significant higher percentage (39%, p<0.03; and 
44%, p<0.03; and 47%, p<0.02, respectively) than patients with IE due to CNE. 
Necrosis was significantly more often present in IE caused by SOTSV (41%, p<0.03), 
miscellaneous pathogens (44%, p<0.05), S. aureus (44%, p<0.01), and Enterococci 
(50%, p<0.01) than in CNE. Furthermore, CNE showed significantly less bacterial 
colonization than IE caused by Stahylococcus aureus (30%, p=0.04) and 
miscellaneous pathogens (67%, p<0.01). Granulocyte infiltrations into the valvular 
cusps were significantly more often associated with Enterococci (78%, p<0.02), S. 
aureus (81%, p<0.01), and SOTSV (88%, p<0.01) than with CNE.  
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Discussion:  
 
This retrospective 10-year study was undertaken at a German university hospital. 
The epidemiology and clinical presentation of patients receiving heart valve surgery 
for IE was described, and NVE was compared with PVE. The aim of this study was to 
delineate damage patterns and differences in clinical presentation associated with 
various pathogens and to evaluate the role of pre- and postoperative diagnostic 
procedures. 
The proportion of NVE in our cohort was high, but still in accordance with recently 
published international data11-13. As expected, IE in the population studied mainly 
involved valves of the left heart. The distribution of infected valves in NVE and PVE 
patients was similar to results found in several other studies on IE15-20.  
The range and distribution of the operative procedures performed in this series was 
similar to published studies, too. According to the literature, most centers preferred 
the insertion of mechanical valves, but with a wide range between 56% and 97%16, 21-
25. 
Characteristics of our study population were largely comparable to those found in the 
literature. Male gender clearly predominated in all groups (total, NVE, PVE). PVE 
patients tended to be older than NVE patients (mean age: 62 vs 57 years). In all 
groups patients’ mean age was in the upper range of similar previously published 
studies22, 26-28. Over the past decade, mean age seems to have increased in patients 
with operated IE of all causes. 
Echocardiography was performed in almost all episodes in this study. Unfortunately 
the type of echocardiography could not be further specified in 50% of the episodes. 
This is due to the retrospective nature of this study with its inherent problems of 
unstandardized documentation. In 95% of the episodes this diagnostic method 
allowed a provisional diagnosis of IE, which emphasizes the role and importance of 
echocardiography in the diagnosis of IE, as has been acknowledged by the important 
role of echocardiography in the revised Duke criteria for the diagnosis of IE13. 
In this study population diabetes mellitus was prevalent at a relatively high rate, 
which may be due to the high mean age of our cohort. Published studies report 
widely varying diabetes rates of 6.5% to 36%24, 29, 30. According to the current 
literature, diabetes mellitus is seen as an independent risk factor for a poor prognosis 
in IE, but this could not be confirmed by our data31-33. Bicuspid aortic valves were 
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reported in 9% to 17% in other series of operated NVE12, 17, 28, 34. The proportion of 
bicuspid aortic valves in this series was low. Perioperative sepsis, including sepsis, 
severe sepsis and septic shock episodes, was present in a relatively high percentage 
in this series, without significant difference between NVE and PVE patients. Only 
Tornos found a similar high sepsis rate of 40% in a mixed NVE-PVE-cohort, and 
Balasubramanian reported a sepsis rate of 33% among operated NVE patients35, 36. 
Other studies reported lower rates of sepsis, e.g. 9% in a mixed NVE-PVE-
population, 18% among operated NVE patients, and 19% in operated PVE patients21, 
25, 37. 
The rates of embolic events and cerebral-embolic events in our study are similar to 
results found in a large French cohort study27. According to the current literature 
embolic events occur in 29.5% to 40% of the IE episodes, and cerebral-embolic 
events in 13% to 20%16, 18, 19, 24, 25, 36, 38. Like in most of these studies, also in our 
population embolic events tended to occur more often in NVE than in PVE patients. 
Pathogen spectra for NVE and PVE episodes in this study are similar to 
spectra observed in other recent comparable investigations36, 38. In NVE episodes S. 
aureus turned out to be the pathogen detected most frequently, and in PVE episodes 
this was S. epidermidis. This is in contrast to older literature, which reported S. 
viridans as the predominating pathogen18, 25. The epidemiology of pathogens causing 
IE is obviously changing, and this study confirms that S. aureus has now become the 
most prevalent pathogen in operated NVE. 
Notably, no HACEK-pathogens were detected in this cohort, although the literature 
suggests HACEK-prevalences of up to 6%12, 21, 29, 39, 40. At the same time, the CNE 
rate in our study was relatively high, both in NVE and PVE. Several studies including 
medical and surgical patients showed widely varying CNE rates between 5.5% and 
46%16, 23-25, 35. Recently, a large international study investigating the benefit of early 
surgical intervention in 610 NVE episodes found a very low CNE rate of only 6%26. 
Reasons for these varying CNE rates may be due to the different inclusion criteria in 
the various studies. Epidemiological investigations on NVE suggest CNE rates 
between 10% and 12%20, 26, 36, 38, 39, whereas surgical case series investigating PVE 
report CNE rates of 21% to 33%18, 23, 37, 41. The literature on PVE epidemiology shows 
rates between 10% and 35%20, 36, 38, 39. In our study, the high CNE rate and the 
absence of HACEK-pathogens may be due to missing standardization of 
                                               
* Authors did not differ between sepsis, severe sepsis or septic shock 
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microbiological diagnostic methods (i.e. application errors, different blood culture 
systems, too short incubation time), the retrospective nature of this study, and 
possibly premature initiation of antibiotic treatment at admitting hospitals in many 
cases. Correct and standardized microbiological testing might have revealed 
HACEK-pathogens and might have also resulted in a lower CNE rate. In our study, 
culturing of resected valve tissue led to the identification of IE-causing pathogens in 
most of the cases, when applied. In contrast, histopathological results of resected 
heart valves did not reveal macroscopic or microscopic pathogen-specific damage 
patterns that allowed to conclude on possible causative pathogens. Lepidi42 and 
Greub43 stated that valve histology remained the gold standard for the diagnosis of 
IE. The current German S2 Guideline on diagnosis and therapy of IE44 also 
recommends the implementation of histopathological examination, especially if 
microbiological culturing, clinical profile and imaging methods do not show clear 
results. However, our findings suggest that histopathologic processing of resected 
valve tissue is not necessary. Instead, in addition to blood cultures, microbiological 
testing should be augmented with cultures of resected valve tissue whenever 
possible. Furthermore, bacterial PCR should be performed on resected valve tissue. 
Several authors agree that PCR is a valuable supplement to the current standard 
workup of resected valve tissue45, 46. PCR is not only more sensitive, specific and 
rapid than valve culture, but also allows identification of the full spectrum of IE 
causing pathogens, especially in CNE episodes 10, 46, 47. Some authors even 
recommend to introduce PCR as a new Duke criterion for the diagnosis of IE45, 48, 49.  
Episodes without detection of pathogens proved to be less severe compared to 
culture-positive IE episodes in this study. The rates of perioperative sepsis, septic 
metastatic foci, local abscesses, vegetation thrombi, embolic events, cerebral-
embolic events and valve perforations were lowest in CNE episodes. 
Histopathological findings confirmed these findings by showing low rates of fibrin 
deposits, ulcerations, necrosis, bacterial colonization and granulocyte infiltrations. On 
the other hand calcification and stenosis was more prevalent in CNE than in culture-
positive IE, which may point towards a longer disease course in such cases with less 
virulent pathogens. Consequently, 30-day mortality in patients with CNE was only 
13%. A recent Swedish study reported a similar low mortality rate of 5% in CNE 
cases50. Similarly, Marks showed a significant lower mortality rate of CNE patients 
compared to patients with culture-positive IE51. In contrast, Zamorano reported that 
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CNE-patients had a higher frequency of valve rupture, valve perforation and heart 
failure, and concluded that their prognosis was worse than in patients with culture-
positive IE52. However, the mortality rate in his study did not differ significantly 
between culture-negative and culture-positive IE. Hoen also found no remarkable 
difference between culture-negative and culture-positive IE cases regarding patient 
characteristics, clinical features, and outcome 53.  
S. epidermidis was the pathogen isolated most often in PVE episodes. It was 
associated with a high rate of single valve affection, and a preference for the aortic 
valve. These results are in agreement with results found in the current literature20, 29, 
39, 54. Low perforation, stenosis and insufficiency rates in S. epidermidis IE in our 
cohort may be a consequence of the high proportion of PVE. Most of the inserted 
prostheses were robust and durable mechanical valves, which rarely break down. 
Episodes caused by S. epidermidis presented with less embolic events than 
episodes caused by S. aureus. This is in agreement with findings by Chu, who noted 
a significant lower rate of embolic and cerebral-embolic events in patients with 
coagulase negative staphylococci NVE compared to patients with S. aureus NVE55, 
56. Similarly, Lalani found that patients with coagulase negative staphylococci PVE 
suffered less embolic events than patients with other forms of IE, although they had 
vegetations in similar frequency57.  
Valvular perforations, prolapses and insufficiencies were present mainly in the NVE 
group, likely because native valves are more vulnerable than mechanical 
prostheses58. IE caused by S. viridans showed the highest valve perforation rate. To 
some extent, this may be due to the high proportion of NVE cases in the S. viridans 
group. Contradictory results on this issue can be found in the literature. Lopez 
reported similar findings, and showed that prosthetic valves were less frequently 
affected in S. viridans IE episodes compared to IE of other origin59. Low mortality, 
sepsis and embolism rates in combination with a high calcification rate found in our 
study support recent observations considering S. viridans a less agressive pathogen 
with lower complication rates and mortality, and a relatively good prognosis59-61.  
In contrast, histologic findings in the SOTSV group showed the lowest calcification 
rate, whereas lymphocytic and granulocytic infiltrates were found more frequently, 
indicating a more vigorous immune response to these pathogens. These results were 
signifcantly different from the findings in S. viridans-infected valves or in CNE. 
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SOTSV IE was associated with the highest rate of embolic events, only IE due to S. 
aureus showed embolic events in similar frequency. Despite this, 30-day mortality of  
SOTSV IE was relatively low, presumably due to a good response to antibiotic 
therapy.  
Cardiac abscesses were observed at a higher rate in PVE than in NVE in this 
study, but such local abscesses did not represent a risk factor for mortality. 
Enterococci presented with the highest abscess rate of all pathogens. Anderson 
found similar results and concluded that enterococcal PVE had a higher likelihood of 
developing intracardiac abcesses62. However, Anderson’s and several other studies 
ranged between 5% and 10% only62-64. The higher abscess rate in this investigation 
may be explained by the surgical patient population studied. The above mentioned 
trials also included medical patients, which may explain the lower abscess rates.  
Enterococci were associated with a relatively high sepsis rate, and a 
preverence for the affection of the aortic valve only. This observation is in 
contradiction to results found in other studies, which reported a single affection of the 
aortic valve in only 34% to 49%64, 65. Still, McDonald found that in enterococcal 
endocarditis vegetations were found predominately at the aortic valve and less likely 
at the mitral valve compared to IE due to other pathogens63. In contrast to the high 
abscess and sepsis rate, enterococcal IE was associated with the lowest rate of 
embolic events and did not show any cerebral-embolic events. Other studies are in 
line with these findings, and also showed low rates of embolic events in enterococcal 
IE, ranging between 26% and 29%, and rates of cerebral-embolic events between 
12% and 21%62, 63, 66. McDonald concluded that Enterococci cause emboli less often 
than S. aureus 63.  
In this investigation, S. aureus IE had a significantly higher rate of embolic 
events than IE due to most other pathogens, and significantly higher rates of 
cerebral-embolic events than IE due to S. viridans, CNE or miscellaneous pathogens. 
Fowler and Miro also reported a significantly higher rate of embolic events including a 
higher rate of cerebral-embolic events in S. aureus IE67, 68. Furthermore, S. aureus IE 
was associated with a significantly higher perioperative sepsis rate than in IE due to 
any other pathogen. Septic metastatic foci were also seen most frequently in S. 
aureus IE. This confirms results of previous studies, which reported significantly 
higher rates of severe sepsis and septic shock among patients with S. aureus IE69-71. 
The higher complication rates of S. aureus IE are reflected in the highest 30-day 
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mortality rate among all pathogen groups in this study. Two large international 
studies reported mortality rates for S. aureus IE of similar magnitude (22% and 20%, 
respectively)67, 68. In these studies, the mortality difference of S. aureus IE compared 
to IE due to other pathogens was significant. In this investigation, however, the 
difference did not reach significance, possibly due to lower power.  
Mortality in our cohort was significantly higher in PVE patients for the 30-day 
and 90-day period, but not for the 15-day period. In comparable studies 30-day 
mortality rates ranged between 4% and 19.5% for NVE patients, and between 15% 
and 36% in PVE patients16, 17, 20-23, 29, 38. Comparison of 30-day mortality rates for the 
periods between 1994 and 1999 and between 2000 and 2005 showed a non-
significant trend towards lower mortality rates. Patients who received biological 
valves had a higher 30-day mortality than patients who received mechanical valves. 
One of the reasons for this phenomenon might be the higher age of the patients who 
received bio-prostheses. Similar findings were reported by Hammermeister and 
Brown, who reported higher mean ages and mortality rates among patients who had 
received bio-prostheses for valve replacement after IE compared to patients with 
mechanical valve replacement72, 73. Lund and Khan only found significantly different 
mean ages, but similar mortality rates for patients with biological and mechanical 
valve replacement after IE74, 75. In the literature age over 70 years, presence of 
annular abscesses, severe sepsis or septic shock, diabetes mellitus, PVE, heart 
failure, S. aureus, cerebral embolization and IE at more than one valve are 
considered independent predictors for hospital mortality: 18, 22, 23, 25, 38, 40, 76. This study 
confirms some of these predictive parameters. In the cohort investigated patients 
older than 70 years were at higher risk for mortality. Furthermore, patients with PVE 
had a higher mortality rate than patients with NVE, and patients with vegetation 
thrombi present at the infected valves were found to have a higher mortality rate, too.  
In conclusion, this study describing the epidemiology of IE at a German tertiary 
center confirms many findings of previous investigations. Although a relatively high 
proportion of patients suffered from sepsis and embolic events the mortality rate was 
similar to those in other national and international studies. The high rate of CNE was 
most likely due to missing standardization of microbiological diagnostic methods, the 
retrospective nature of this investigation, and premature initiation of antibiotic 
treatment at admitting hospitals in many cases. Some IE pathogens were found to be 
associated with a characteristic clinical presentation, e.g. S. aureus with a high rate 
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of sepsis and septic embolic events, Enterococci with a high rate of annular 
abscesses, and Viridans streptococci with a high rate of valve perforations. Such 
associations may allow a first estimate of the causative pathogen, but the 
associations are too weak for clinical decision making.  
In contrast to the clinical findings, results of histopathologic examinations did not 
reveal pathogen-specific damage patterns in this investigation and added little 
information overall. Therefore, histopathologic workup of resected heart valves can 
be omitted. Instead, in addition to blood cultures, microbiological testing should be 
complemented with cultures of resected valve tissue whenever possible. 
Furthermore, new techniques such as bacterial PCR from resected valve tissue 
should be established as routine diagnostic tool and might be especially helpful in 
culture-negative IE.  
 
 
 
References 
 
1. Blaas SH ED, Glück T. Infektiöse Endokarditis. Arzneimitteltherapie 
2002(20):362-74. 
2. Hoen B. Epidemiology and antibiotic treatment of infective endocarditis: an 
update. Heart 2006;92(11):1694-700. 
3. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 
2001;345(18):1318-30. 
4. German guidelines for the diagnosis and management of infective 
endocarditis. Int J Antimicrob Agents 2007;29(6):643-57. 
5. Delahaye F, Alla F, Beguinot I, et al. In-hospital mortality of infective 
endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect 
Dis 2007;39(10):849-57. 
6. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. 
Nationwide increase in the number of hospitalizations for illicit injection drug use-
related infective endocarditis. Clin Infect Dis 2007;45(9):1200-3. 
7. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363(9403):139-49. 
8. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of population-
based studies of infective endocarditis. Chest 2007;132(3):1025-35. 
9. Yiu KH, Siu CW, Lee KL, et al. Emerging trends of community acquired 
infective endocarditis. Int J Cardiol 2007;121(1):119-22. 
10. Breitkopf C, Hammel D, Scheld HH, Peters G, Becker K. Impact of a Molecular 
Approach to Improve the Microbiological Diagnosis of Infective Heart Valve 
Endocarditis. Circulation 2005;111(11):1415-21. 
11. Naber CK, Erbel R, Baddour LM, Horstkotte D. New guidelines for infective 
endocarditis: a call for collaborative research. Int J Antimicrob Agents 
2007;29(6):615-6. 
F. Zauner 27 
12. Cecchi E, Forno D, Imazio M, et al. New trends in the epidemiological and 
clinical features of infective endocarditis: results of a multicenter prospective study. 
Ital Heart J 2004;5(4):249-56. 
13. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective 
endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis 
Service. Am J Med 1994;96(3):200-9. 
14. Kupferwasser LI, Darius H, Müller AM, et al. Diagnosis of culture-negative 
endocarditis: The role of the Duke criteria and the impact of transesophageal 
echocardiography. American Heart Journal 2001;142(1):146-52. 
15. Akowuah EF, Davies W, Oliver S, et al. Prosthetic valve endocarditis: early 
and late outcome following medical or surgical treatment. Heart 2003;89(3):269-72. 
16. Cotrufo M, Carozza A, Romano G, De Feo M, Della Corte A. Infective 
endocarditis of native cardiac valves: 22 years' surgical experience. J Heart Valve 
Dis 2001;10(4):478-85. 
17. Dyson C, Barnes RA, Harrison GA. Infective endocarditis: an epidemiological 
review of 128 episodes. J Infect 1999;38(2):87-93. 
18. Horacio Casabe J, Deschle H, Cortes C, et al. [Predictors of hospital mortality 
in 186 cases of active infective endocarditis treated in a tertiary medical center 
(1992-2001)]. Rev Esp Cardiol 2003;56(6):578-85. 
19. Jassal DS, Hassan A, Buth KJ, Neilan TG, Koilpillai C, Hirsch GM. Surgical 
management of infective endocarditis. J Heart Valve Dis 2006;15(1):115-21. 
20. Loupa C, Mavroidi N, Boutsikakis I, et al. Infective endocarditis in Greece: a 
changing profile. Epidemiological, microbiological and therapeutic data. Clin Microbiol 
Infect 2004;10(6):556-61. 
21. Alexiou C, Langley SM, Stafford H, Lowes JA, Livesey SA, Monro JL. Surgery 
for active culture-positive endocarditis: determinants of early and late outcome. Ann 
Thorac Surg 2000;69(5):1448-54. 
22. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. 
Surgical treatment of active infective endocarditis: a continued challenge. J Thorac 
Cardiovasc Surg 2007;133(1):144-9. 
23. Murashita T, Sugiki H, Kamikubo Y, Yasuda K. Surgical results for active 
endocarditis with prosthetic valve replacement: impact of culture-negative 
endocarditis on early and late outcomes. Eur J Cardiothorac Surg 2004;26(6):1104-
11. 
24. Romano G, Carozza A, Della Corte A, et al. Native versus primary prosthetic 
valve endocarditis: comparison of clinical features and long-term outcome in 353 
patients. J Heart Valve Dis 2004;13(2):200-8; discussion 8-9. 
25. Tugtekin SM, Alexiou K, Wilbring M, et al. Native infective endocarditis: which 
determinants of outcome remain after surgical treatment? Clin Res Cardiol 
2006;95(2):72-9. 
26. Cabell CH, Abrutyn E, Fowler VG, Jr., et al. Use of surgery in patients with 
native valve infective endocarditis: results from the International Collaboration on 
Endocarditis Merged Database. Am Heart J 2005;150(5):1092-8. 
27. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: 
results of a 1-year survey in France. Jama 2002;288(1):75-81. 
28. Tleyjeh IM, Steckelberg JM, Murad HS, et al. Temporal trends in infective 
endocarditis: a population-based study in Olmsted County, Minnesota. Jama 
2005;293(24):3022-8. 
29. Guerra JM, Tornos MP, Permanyer-Miralda G, Almirante B, Murtra M, Soler-
Soler J. Long term results of mechanical prostheses for treatment of active infective 
endocarditis. Heart 2001;86(1):63-8. 
F. Zauner 28 
30. Tugtekin S, Matschke K, Daubner D, et al. Prosthetic valve endocarditis: 
importance of surgical treatment. Thorac Cardiovasc Surg 2007;55(2):94-8. 
31. Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with infective 
endocarditis: a propensity score analysis. Clin Infect Dis 2007;44(3):364-72. 
32. Kourany WM, Miro JM, Moreno A, et al. Influence of diabetes mellitus on the 
clinical manifestations and prognosis of infective endocarditis: a report from the 
International Collaboration on Endocarditis-Merged Database. Scand J Infect Dis 
2006;38(8):613-9. 
33. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of 
infectious endocarditis in patients with type II diabetes mellitus. J Diabetes 
Complications 2007;21(6):403-6. 
34. Chu J, Wilkins G, Williams M. Review of 65 cases of infective endocarditis in 
Dunedin Public Hospital. N Z Med J 2004;117(1200):U1021. 
35. Balasubramanian SK, Behranwala A, Devbhandari M, et al. Predictors of 
mortality in early surgical intervention for active native valve endocarditis and 
significance of antimicrobial therapy: a single-center experience. J Heart Valve Dis 
2005;14(1):15-22. 
36. Tornos P, Iung B, Permanyer-Miralda G, et al. Infective endocarditis in 
Europe: lessons from the Euro heart survey. Heart 2005;91(5):571-5. 
37. Castillo JC, Anguita MP, Torres F, et al. Long-term prognosis of early and late 
prosthetic valve endocarditis. Am J Cardiol 2004;93(9):1185-7. 
38. Mouly S, Ruimy R, Launay O, et al. The changing clinical aspects of infective 
endocarditis: descriptive review of 90 episodes in a French teaching hospital and risk 
factors for death. J Infect 2002;45(4):246-56. 
39. Ferreiros E, Nacinovich F, Casabe JH, et al. Epidemiologic, clinical, and 
microbiologic profile of infective endocarditis in Argentina: a national survey. The 
Endocarditis Infecciosa en la Republica Argentina-2 (EIRA-2) Study. Am Heart J 
2006;151(2):545-52. 
40. Tran CT, Kjeldsen K. Endocarditis at a tertiary hospital: reduced acute 
mortality but poor long term prognosis. Scand J Infect Dis 2006;38(8):664-70. 
41. Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve endocarditis: who 
needs surgery? A multicentre study of 104 cases. Heart 2005;91(7):954-9. 
42. Lepidi H, Casalta JP, Gouriet F, Collart F, Habib G, Raoult D. Infective 
endocarditis incidentally discovered by pathological examination. J Clin Pathol 
2008;61(2):233-4. 
43. Greub G, Lepidi H, Rovery C, et al. Diagnosis of infectious endocarditis in 
patients undergoing valve surgery. The American Journal of Medicine 
2005;118(3):230-8. 
44. Naber CK. [S2 Guideline for diagnosis and therapy of infectious endocarditis]. 
Z Kardiol 2004;93(12):1005-21. 
45. Marin M, Munoz P, Sanchez M, et al. Molecular diagnosis of infective 
endocarditis by real-time broad-range polymerase chain reaction (PCR) and 
sequencing directly from heart valve tissue. Medicine (Baltimore) 2007;86(4):195-
202. 
46. Voldstedlund M, Norum Pedersen L, Baandrup U, Klaaborg KE, Fuursted K. 
Broad-range PCR and sequencing in routine diagnosis of infective endocarditis. 
Apmis 2008;116(3):190-8. 
47. Grijalva M, Horvath R, Dendis M, Erny J, Benedik J. Molecular diagnosis of 
culture negative infective endocarditis: clinical validation in a group of surgically 
treated patients. Heart 2003;89(3):263-8. 
F. Zauner 29 
48. Bosshard PP, Kronenberg A, Zbinden R, Ruef C, Bottger EC, Altwegg M. 
Etiologic diagnosis of infective endocarditis by broad-range polymerase chain 
reaction: a 3-year experience. Clin Infect Dis 2003;37(2):167-72. 
49. Millar B, Moore J, Mallon P, et al. Molecular diagnosis of infective 
endocarditis--a new Duke's criterion. Scand J Infect Dis 2001;33(9):673-80. 
50. Werner M, Andersson R, Olaison L, Hogevik H, Endocarditis TS. A 10-year 
survey of blood culture negative endocarditis in Sweden: Aminoglycoside therapy is 
important for survival. Scand J Infect Dis 2008;40(4):279-85. 
51. Marks P, Gogova M, Kromery V, Jr. Culture negative endocarditis: data from 
the national survey in Slovakia. Postgrad Med J 2002;78(915):61. 
52. Zamorano J, Sanz J, Moreno R, et al. Comparison of outcome in patients with 
culture-negative versus culture-positive active infective endocarditis. Am J Cardiol 
2001;87(12):1423-5. 
53. Hoen B, Selton-Suty C, Lacassin F, et al. Infective endocarditis in patients with 
negative blood cultures: analysis of 88 cases from a one-year nationwide survey in 
France. Clin Infect Dis 1995;20(3):501-6. 
54. Wang A, Athan E, Pappas PA, et al. Contemporary Clinical Profile and 
Outcome of Prosthetic Valve Endocarditis. JAMA 2007;297(12):1354-61. 
55. Chu VH, Cabell CH, Abrutyn E, et al. Native valve endocarditis due to 
coagulase-negative staphylococci: report of 99 episodes from the International 
Collaboration on Endocarditis Merged Database. Clin Infect Dis 2004;39(10):1527-
30. 
56. Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase-negative 
staphylococci as a cause of native valve endocarditis. Clin Infect Dis 2008;46(2):232-
42. 
57. Lalani T, Kanafani ZA, Chu VH, et al. Prosthetic valve endocarditis due to 
coagulase-negative staphylococci: findings from the International Collaboration on 
Endocarditis Merged Database. Eur J Clin Microbiol Infect Dis 2006;25(6):365-8. 
58. Bottio T, Casarotto D, Thiene G, Caprili L, Angelini A, Gerosa G. Leaflet 
escape in a new bileaflet mechanical valve: TRI technologies. Circulation 
2003;107(18):2303-6. 
59. Lopez J, San Roman JA, Revilla A, et al. [Clinical, echocardiographic and 
prognostic profile of Streptococcus viridans left-sided endocarditis]. Rev Esp Cardiol 
2005;58(2):153-8. 
60. Giannitsioti E, Chirouze C, Bouvet A, et al. Characteristics and regional 
variations of group D streptococcal endocarditis in France. Clin Microbiol Infect 
2007;13(8):770-6. 
61. Hoen B, Chirouze C, Cabell CH, et al. Emergence of endocarditis due to group 
D streptococci: findings derived from the merged database of the International 
Collaboration on Endocarditis. Eur J Clin Microbiol Infect Dis 2005;24(1):12-6. 
62. Anderson DJ, Olaison L, McDonald JR, et al. Enterococcal prosthetic valve 
infective endocarditis: report of 45 episodes from the International Collaboration on 
Endocarditis-merged database. Eur J Clin Microbiol Infect Dis 2005;24(10):665-70. 
63. McDonald JR, Olaison L, Anderson DJ, et al. Enterococcal endocarditis: 107 
cases from the international collaboration on endocarditis merged database. Am J 
Med 2005;118(7):759-66. 
64. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: 
can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34(2):159-
66. 
F. Zauner 30 
65. Fernandez-Guerrero ML, Herrero L, Bellver M, Gadea I, Roblas RF, de 
Gorgolas M. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized 
patients with enterococcal bacteraemia. J Intern Med 2002;252(6):510-5. 
66. Fernandez Guerrero ML, Goyenechea A, Verdejo C, Roblas RF, de Gorgolas 
M. Enterococcal endocarditis on native and prosthetic valves: a review of clinical and 
prognostic factors with emphasis on hospital-acquired infections as a major 
determinant of outcome. Medicine (Baltimore) 2007;86(6):363-77. 
67. Fowler VG, Jr., Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a 
consequence of medical progress. Jama 2005;293(24):3012-21. 
68. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve 
infective endocarditis: report of 566 episodes from the International Collaboration on 
Endocarditis Merged Database. Clin Infect Dis 2005;41(4):507-14. 
69. Hill EE, Peetermans WE, Vanderschueren S, Claus P, Herregods MC, 
Herijgers P. Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus 
infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27(6):445-50. 
70. Nadji G, Remadi JP, Coviaux F, et al. Comparison of clinical and 
morphological characteristics of Staphylococcus aureus endocarditis with 
endocarditis caused by other pathogens. Heart 2005;91(7):932-7. 
71. Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact of surgery 
in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 2007;83(4):1295-
302. 
72. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients 
aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. 
J Thorac Cardiovasc Surg 2008;135(4):878-84; discussion 84. 
73. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, 
Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical 
versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J 
Am Coll Cardiol 2000;36(4):1152-8. 
74. Khan SS, Trento A, DeRobertis M, et al. Twenty-year comparison of tissue 
and mechanical valve replacement. J Thorac Cardiovasc Surg 2001;122(2):257-69. 
75. Lund O, Bland M. Risk-corrected impact of mechanical versus bioprosthetic 
valves on long-term mortality after aortic valve replacement. J Thorac Cardiovasc 
Surg 2006;132(1):20-6. 
76. Wang A, Pappas P, Anstrom KJ, et al. The use and effect of surgical therapy 
for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, 
international cohort. Am Heart J 2005;150(5):1086-91. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F. Zauner 31 
Abbreviations 
 
av only aortic valve affected only 
av & mv aortic and mitral valve affected 
CNE  Culture-negative Endocarditis 
HACEK Haemophilus species, Actinobacillus actinomycetemcomitans, 
Cardiobacterium hominis, Eikenella corrodens, Klingella species 
IE    infective endocarditis 
ICU  Intensive Care Unit 
IMC  Intermediate Care Unit 
my only mitral valve affected only 
MRI  Magnetic Resonance Imaging 
ns  no significance 
NVE    native valve endocarditis 
pv/tv only pulmonary or tricuspid valve affected only 
PCR  Polymerase Chain Reaction 
PVE    prosthetic valve endocarditis 
SOTSV Streptococci other than S. viridans 
TEE  Transesophageal Echocardiography 
TTE  Transthoracal Echocardiography 
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  NVE PVE Total NVE vs PVE Correlation with 
          30-day Mortality 
Number of episodes 84% (177) 16% (34) 
100% (211; in 205 
patients) - - 
Sex: male / female 75% / 25% 76.5% / 23.5% 75% / 25% - ns (p>0.4) 
Median (mean; range) age (in years) 57 (60; 22-80) 62 (66; 24-79) 61  (58; 22-80) - - 
age<60y vs age>70y 77% (83) / 23% (25) 
50% (11) / 50% 
(11) 72% (94) / 28% (36) - p=0.01 
Predisposing Factors           
    bicuspid aortic valve 8.5% (15) - 7% (15) - ns (p>0.1) 
    diabetes mellitus 23% (40) 32% (11) 24% (51) ns1 (p>0.3) ns (p>0.9) 
    sepsis 39.5% (70) 32% (11) 38% (81) ns (p>0.4) ns (p>0.06) 
    septic metastatic foci 25% (45) 12% (4) 23% (49) ns (p>0.1) ns (p>0.9) 
Applied diagnostic methods           
    echocardiography2 97% (172) 100% (34) 98% (206) - - 
    blood culture 100% (177) 100% (34) 100% (211) - - 
    intraoperative documentation 100% (177) 100% (34) 100% (211) - - 
    histopathology results 95.5% (169) 56% (19) 89% (188) - - 
Type of surgery           
    single valve surgery 88% (156) 100% (34) 90% (190) - ns (p>0.1) 
        bioprothesis 16% (28) 38% (13) 19% (41) - - 
        mechanical prosthesis 58% (102) 59% (20) 58% (122) - - 
        reconstruction of valve 15% (26) 3% (1) 13% (27) - - 
    multiple valve surgery (2 or more valves) 11% (19) - 9% (19) - ns (p>0.1) 
        reconstruction + bioprothesis 3.5% (6) - 3% (6) - - 
        reconstruction + mechanical prothesis 7% (12) - 6% (12) - - 
        reconstruction + bio- and mechanical prothesis 0.5% (1) - 0.5% (1) - - 
    type of surgery not specified 1% (2) - 1% (2) - - 
Isolated pathogens 68% (121) 65% (22) 68% (143)     
    S. aureus 21.5% (38) 11.5% (4) 20% (42) ns (p>0.1) ns (p>0.1) 
    S. viridans 16% (29) 3% (1) 14% (30) p<0.02 ns (p>0.4) 
    S. epidermidis 4% (7) 17.5% (6) 6% (13) p<0.01 ns (p>0.9) 
    SOTSV3 8.5% (15) 9% (3) 8.5% (18) ns (p>0.9) ns (p>0.6) 
    Enterococci 10% (17) 9% (3) 9.5% (20) ns (p>0.8) ns (p>0.9) 
    Miscellaneous pathogens 5% (9) 9% (3) 6% (12) ns (p>0.4) ns (p>0.5) 
    Mixed infections 3% (6) 6% (2) 4% (8) ns (p>0.5) ns (p>0.8) 
    Culture negative endocarditis 32% (56) 35% (12) 32% (68) ns (p>0.6 ns (p>0.7) 
Infected valves           
    one valve / multiple valves 78.5% (139) / 21.5% (38) 94% (32) / 6% (2) 81% (171) / 19% (40) p<0.04 p<0.02 
    aortic valve only 44.5% (79) 70.5% (24) 49% (103) p<0.01 p>0.4 
    mitral valve only 29.5% (52) 20.5% (7) 28% (59) ns (p>0.2) ns (p>0.7) 
    aortic + mitral 20% (35) 6% (2) 17.5% (37) ns (p=0.052) p<0.01 
    other valves 6% (10) 3% (1) 5.5% (11) - - 
Valve damage           
    valve stenosis 14% (25) 9% (3) 13% (28) - ns (p>0.5) 
    presence of abscesses 26% (46) 59% (20) 31% (66) p<0.01 ns (p>0.1) 
    perforation of valvular cusps 79% (140) 29% (10) 71% (150) - ns (p>0.5) 
    valve insufficiency 94% (167) 76.5% (26) 91.5% (193) - ns (p>0.6) 
    valve prolapse 34% (60) 12% (4) 30% (64) - ns (p>0.07) 
Histological  findings           
    vegetations 89% (157) 82% (28) 88% (185) ns (p>0.3) ns (p>0.2) 
    vegetation thrombi 58% (102) 41% (14) 55% (116) ns (p>0.07) p<0.03 
    calcifications 83% (141) 91% (21) 84% (162) ns (p>0.2) ns (p>0.1) 
    fibrin deposits 44% (74) 48% (10) 44% (84) ns (p>0.7) ns (p>0.6) 
    ulcerations 35% (59) 16% (3) 33% (62) ns (p>0.09) ns (p>0.7) 
    necrosis 33% (56) 21% (4) 32% (60) ns (p>0.2) ns (p>0.9) 
    bacterial colonization 26% (45) 16% (3) 25% (48) ns (p>0.2) ns (p>0.4) 
    lymphocytes 25% (45) 12% (4) 23% (49) ns (p>0.08) ns (p>0.06) 
    granulocytes 63% (111) 32% (11) 58% (122) p<0.01 ns (p>0.5) 
Embolic events 36% (64) 21% (7) 34% (71) ns (p>0.07) ns (p>0.7) 
    single embolic event 25% (45) 12% (4) 23% (49) ns (p>0.08) ns (p>0.6) 
    multiple embolic events 9% (16) 9% (3) 9% (19) ns (p>0.9) ns (p>0.3) 
    unknown number of embolic events 2% (3) - 1.5% (3) - - 
Sites of emboli4           
    central nervous system 17% (30) 18% (6) 17% (36) ns (p>0.9) ns (p>0.5) 
    extremities 8% (15) 6% (2) 8% (17) ns (p>0.5) ns (p>0.2) 
    spleen 5% (9) 6% (2) 5% (11) ns (p>0.8) ns (p>0.7) 
    lung 3.5% (6) - 3% (6) ns (p>0.1) ns (p>0.1) 
    kidney 3% (5) - 2.5% (5) ns (p>0.1) ns (p>0.2) 
    retina 3% (5) - 2.5% (5) ns (p>0.1) ns (p>0.2) 
    other sites 5.5% (9) - 4.5% (9) ns (p>0.07) ns (p>0.8) 
Mortality           
    15-day mortality 8.5% (15) 21% (7) 10% (22) ns (p=0.052) - 
    30-day mortality 11% (20) 29% (10) 14% (30) p<0.01 - 
    90-day mortality 14% (24) 32% (11) 17% (35) p<0.01 - 
    median (mean) time to death after surgery 7.5 (10) 5 (8) 7 (9) - -     (in days; for the 30-day period) 
Duration of hospital stay after surgery           
    median (mean) time at IMC/ICU5 (in days) 4 (6) 7 (15) 4 (7) - - 
    median (mean) time at hospital (in days) 12.5 (14) 15 (21) 13 (15) - - 
      
Table 1: Study Population      
 1ns = no significance     
 2includes transesophageal and/or transthoracal echocardiography   
 3 SOTSV = Streptococci other than S. viridans    
 
4 multiple embolic events seperated into single 
embolic events    
 5 Intermediate Care Unit / Intensive Care Unit    
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Pathogen n %
Staphylococcus aureus 42 20%
Streptococcus viridans 30 14%
       S. viridans spp. 11 5%
       S. mitis 9 4%
       S. sanguis 6 3%
       S. anginosus ("S. milleri") 4 2%
Enterococci 20 9.5%
       Enterococcus faecalis 12 6%
       Enterococcus spp. 6 2.5%
       Enterococcus faecium 2 1%
1SOTSV 18 8.5%
       S. bovis (group D) 8 4%
       S. agalactiae (group B) 3 1%
       S. pneumoniae 2 1%
       S. haemolyticus (group C) 2 1%
       S. beta-haemolyzing 1 0.5%
       S. equisimilis 1 0.5%
       S. anhaemolyticus 1 0.5%
Staphylococcus epidermidis 13 6%
Miscellaneous pathogens 12 6%
       Escherichia coli 2 1%
       Aerococcus viridans 1 0.5%
       Candida albicans 1 0.5%
       Enterobacter cloacae 1 0.5%
       Gemella morbilorum 1 0.5%
       Propionibacterium acne 1 0.5%
       Staphylococcus caprae 1 0.5%
       Staphylococcus xylosus 1 0.5%
       Stenotrophomonas maltophilia (Xanthomonas) 1 0.5%
       Staphylococcus spp. 1 0.5%
       Gram-positive Coccus 1 0.5%
Mixed infections 8 4%
       Staphylococcus aureus + Enterococcus spp. 2 1%
       Enterobacter cloacae + Enterobacter amnigenius 1 0.5%
       Enterococcus faecalis + Streptococcus bovis 1 0.5%
       Staphylococcus aureus + Enterococcus faecalis 1 0.5%
       Streptococcus bovis + Enterococcus spp. 1 0.5%
       Streptococcus bovis + Streptococcus equisimilis 1 0.5%
       Streptococcus mitis + Staphylococcus aureus 1 0.5%
Culture negative 68 32%
       no detected pathogen 66 31%
       history of rheumatic endocarditis 2 1%
TOTAL 211 100%
1SOTSV = Streptococci other than Streptococcus viridans
Table 2: Detected Pathogens  
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 Valve Damage Pattern 
  total NVE PVE one valve3 av only4 mv only5 pv/tv only6     
Enterococci 10% (20) 85% (17) 15% (3) 80% (16) 70% (14) 10% (2) 0% (0)     
CNE1 33% (68) 82% (56) 18% (12) 88% (60) 51.5% (35) 35.5% (24) 1.5% (1)     
Misc.pathogens 6% (12) 75% (9) 25% (3) 58% (7) 42% (5) 8% (1) 8% (1)     
S. aureus 21% (42) 90.5% (38) 9.5% (4) 88% (37) 40.5% (17) 40.5% (17) 7% (3)     
S. epidermidis 6% (13) 54% (7) 46% (6) 92% (12) 61.5% (8) 23% (3) 8% (1)     
SOTSV2 9% (18) 83% (15) 17% (3) 67% (12) 56% (10) 6% (1) 6% (1)     
S. viridans 15% (30) 97% (29) 3% (1) 67% (20) 37% (11) 27% (8) 3% (1)     
TOTAL 100% (203) 84% (171) 16% (32) 81% (164) 49% (100) 28% (56) 4% (8)     
                   
 av & mv7 bilateral IE               
Enterococci 15% (3) 5% (1)               
CNE1 12% (8) 0% (0)               
Misc.pathogens 42% (5) 0% (0)               
S. aureus 12% (5) 0% (0)               
S. epidermidis 8% (1) 0% (0)               
SOTSV2 28% (5) 6% (1)               
S. viridans 33% (10) 0% (0)               
TOTAL 18% (37) 1% (2)               
                   
                   
                   
 Clinical Findings 
  30d-lethality sepsis septic focui embolic events cerebral emb. veg. thrombi vegetations     
Enterococci 15% (3) 55% 11 45% 9 10% 2 0% 0 55% 11 100% 20     
CNE1 13% 9 13% 9 6% 4 19% 13 6% 4 31% 21 71% 48     
Misc.pathogens 8% 1 17% 2 8% 1 17% 2 8% 1 67% 8 92% 11     
S. aureus 21% 9 81% 34 45% 19 64% 27 45% 19 74% 31 98% 41     
S. epidermidis 15% 2 46% 6 15% 2 31% 4 15% 2 69% 9 92% 12     
SOTSV2 11% 2 50% 9 39% 7 67% 12 28% 5 72% 13 94% 17     
S. viridans 10% 3 27% 8 20% 1 33% 10 17% 5 60% 18 93% 28     
TOTAL 14% (29) 39% 79 24% 48 34.5% 70 18% 36 55% 92 87% 177     
                   
  abscesses perforations insufficiency stenosis prolapse         
Enterococci 60% 12 85% 17 100% 20 15% 3 25% 5         
CNE1 18% 12 54% 37 88% 60 22% 15 34% 23         
Misc.pathogens 25% 3 67% 8 83% 10 17% 2 17% 2         
S. aureus 33% 14 81% 34 93% 39 5% 2 26% 11         
S. epidermidis 46% 6 54% 7 69% 9 0% 0 23% 3         
SOTSV2 39% 7 78% 14 100% 18 6% 1 22% 4         
S. viridans 37% 11 90% 27 100% 30 10% 3 47% 14         
TOTAL 32% 65 71% 144 92% 186 13% 26 30.5% 62         
                   
                   
                   
 Histological Findings     
  calcification fibrin deposits ulcerations necrosis slime mold lymphocytes granulocytes     
Enterococci 85% 17 61% 11 44% 8 50% 9 32% 6 28% 5 78% 14     
CNE1 95% 59 32% 20 18% 11 14.5% 9 13% 8 26% 16 45% 28     
Misc.pathogens 82% 9 70% 7 44% 4 44% 4 67% 6 33% 3 67% 6     
S. aureus 72% 26 46% 17 39% 14 44% 16 30% 11 22% 8 81% 29     
S. epidermidis 80% 8 50% 5 40% 4 40% 4 40% 4 20% 2 70% 7     
SOTSV2 53% 9 65% 11 47% 8 41% 7 29% 5 35% 6 88% 15     
S. viridans 93% 28 40% 12 33% 10 30% 9 23% 7 23% 7 57% 17     
TOTAL 84% 156 45% 83 32% 59 32% 58 35.5% 47 26% 47 64% 116     
                   
                   
1 CNE   
2 SOTSV= Streptococci other than Streptococcus 
viridans    3 one valve affected only     
4 aortic valve affected only  5 mitral valve affected only       
6 pulmonary or tricuspid valve affected 
only   
7 aortic and mitral valve 
affected                  
                   
                   
Table 3: Correlated Data                
(episodes with two detected pathogens not included; 198 patients; 203 episodes)          
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Table IV: Kaplan-Meier Survival Function – 30 days 
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Table V: Kaplan-Meier Survival Function – 90 days 
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